BAX Baxter International Inc.

Baxter Introduces New Safety Management System and Software Updates for Sigma Spectrum Infusion System at ASHP Meeting

Today at the American Society of Health-System Pharmacists (ASHP) 2016 Midyear Meeting, Baxter International Inc. (NYSE: BAX) announced the launch of the Sigma Spectrum Safety Management System, which adds features designed to help minimize infusion programming risks. The first is Baxter’s Infusion Analytics application, a software solution that provides advanced infusion data analysis and graphical reporting to help identify potential pump programming errors. The second is a suite of Remote Professional Services that offers 24/7 service and technical support along with regular cybersecurity monitoring and reporting.

“Baxter is committed to innovative technology for medication delivery, and Baxter’s new Safety Management System further reinforces Sigma Spectrum’s leadership helping hospitals meet their infusion safety goals,” said David Ferguson, Global Head of Baxter’s Fluid Systems franchise. “The new Infusion Analytics application provides an enhanced user interface designed to make infusion data easy to interpret, and new Remote Professional Services add an additional level of technical support to help protect data and maximize pump performance.”

These updates join existing Sigma Spectrum features including the Master Drug Library (MDL) and Gateway. The MDL allows users to create and customize a list of medications and fluids within medically appropriate dose ranges to guide safe programming, avoiding mistakes before they reach the patient. The Gateway is a Web-based tool to publish drug libraries to the infusion pump fleet and view Continuous Quality Improvement (CQI) data. Baxter is also collaborating with Omnicell® to include an initial integration with Omnicell’s Performance Center software, creating an efficient workflow for the pharmacy to access and review both infusion and medication data in one place.

Sigma Spectrum also includes features like integration with electronic medical record (EMR) systems—including Cerner® and Epic®—to help streamline clinical workflow and improve accuracy of IV infusion documentation.

About Sigma Spectrum Infusion System

Sigma Spectrum’s hardware works in concert with the pump’s software to encourage use of innovative features that are designed to help enhance patient safety and clinician efficiency. For example, the pumps automatically default to the installed drug library without requiring clinicians to take extra steps to “opt-in,” and drug library updates can be delivered wirelessly to pumps in the facility without interrupting clinical workflow. Sigma Spectrum is also the only pump to include a built-in Dose/Rate Change Error Prevention Feature, which helps clinicians protect high-risk infusions during titrations, and allows pharmacists to customize dose change limits for individual drugs. The Sigma Spectrum pump also includes built-in real-time location tracking of equipment within a facility to protect against misplacement, enhanced data analytics and use of standard IV set technology that can yield up to 53 percent cost savings in IV tubing sets and 30 percent reduction in IV tubing use.1

Rx Only. For the safe and proper use of this device, refer to the appropriate operator’s manuals.

About Baxter

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Forward-Looking Statements

This release includes forward-looking statements concerning Baxter's Sigma Spectrum Infusion Systems and related performance data, including anticipated benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; breaches or failures of the company’s information technology systems, changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter and Sigma Spectrum are trademarks of Baxter International Inc.

Cerner is a registered trademark of Cerner Corporation and/or its subsidiaries.

Epic is a registered trademark of Epic Systems Corporation in the United States and/or in other countries.

Omnicell is a registered trademark of Omnicell, Inc. in the United States and internationally.

1 Data on File. Baxter Healthcare Corporation. Total cost of ownership standard set technology inventory and cost reduction data 2011- 2013. *Data provided by these facilities. Baxter makes no guarantee of cost savings.

EN
05/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Baxter International Inc.

Moody's Ratings assigns Baa3 rating to Baxter's senior notes; outlook ...

Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...

Baxter International Inc.: Update following downgrade to Baa3

Our credit view of this issuer reflects its elevated financial leverage, with delays in reaching previously stated deleveraging targets.

Moody's Ratings downgrades Baxter to Baa3/P-3; outlook is stable

Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...

Moody's Ratings reviews Baxter's Baa2/P-2 ratings for downgrade

Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...

Moody's Ratings affirms Baxter at Baa2; revises outlook to negative fr...

Moody's Ratings (Moody's) affirmed Baxter International Inc.'s (Baxter) ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. At the same time, we revised the outlook to negative from stable. The ratings affirmation considers Baxter's good scale and diversity as...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch